Deferasirox and Rifadin IV Intravenous
Determining the interaction of Deferasirox and Rifadin IV Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using deferasirox together with rifAMPin. Combining these medications may reduce the blood levels and effects of deferasirox. You may not be able to take rifAMPin while you are receiving treatment with deferasirox, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with inducers of uridine diphosphate glucuronosyltransferase (UGT) may decrease the plasma concentrations of deferasirox, which is primarily metabolized by UGT1A1- and UGT1A3-mediated glucuronidation. In healthy volunteers, administration of a single 30 mg/kg dose of deferasirox with the potent UGT inducer rifampin (600 mg/day for 9 days) resulted in a reduction of deferasirox systemic exposure (AUC) by 44%. The effect of other UGT inducers on the pharmacokinetics of deferasirox is unknown.
MANAGEMENT: The concomitant use of deferasirox with potent UGT inducers such as rifampin, phenytoin, phenobarbital, carbamazepine, and ritonavir should generally be avoided. Otherwise, consideration should be given to increasing the initial dosage of deferasirox to 30 mg/kg, with subsequent adjustments made according to serum ferritin levels and clinical response.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: deferasirox
Brand name: Exjade, Jadenu, Jadenu Sprinkle
Synonyms: n.a.
Generic Name: rifampin
Brand name: Rifadin IV, Rifadin, Rimactane
Synonyms: Rifadin IV (Intravenous), Rifadin IV
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Deferasirox-Rifamate
- Deferasirox-Rifampin
- Deferasirox-Rifampin and Isoniazid
- Deferasirox-Rifampin Capsules
- Deferasirox-Rifampin Injection
- Deferasirox-Rifampin Intravenous
- Rifadin IV Intravenous-Deferasirox Sprinkle Granules
- Rifadin IV Intravenous-Deferasirox Tablets
- Rifadin IV Intravenous-Deferasirox Tablets For Oral Suspension
- Rifadin IV Intravenous-Deferiprone
- Rifadin IV Intravenous-Deferiprone Oral Solution
- Rifadin IV Intravenous-Deferiprone Tablets